Abstract
Objective: To determine whether diltiazem therapy decreases proteinuria during pregnancy in women with chronic renal disease, resulting in decreased risk of pre-eclampsia, preterm delivery and intrauterinefetal growth restriction.Methods: We undertook retrospective data collection by chart review of pregnant women with chronic renal disease. Women treated with and without diltiazem were comparedby independent t test analysis.Results: Seven women were eligible for inclusion in the study. Individual patient trends revealed decreased or attenuated increase in proteinuria acrossgestation with diltiazem therapy. Mean arterial pressure was also decreased in the therapy group compared to increased pressure in the third trimester in the group with no therapy. The incidence of fetalgrowth restriction and need for labor induction were lower in the diltiazem-treated group.Conclusions: Diltiazem, a non-dihydropyridine calcium channel antagonist, decreases proteinuria andpreserves renal structure and function and should be considered an alternative to angiotensin converting enzyme inhibitors in pregnancy in women with chronic renal disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
